Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Accumulated Expenses (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Accumulated Expenses for 7 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 68.21% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Dec 2025, down 68.21%, and an annual FY2025 reading of $3.0 million, down 68.21% over the prior year.
  • Accumulated Expenses was $3.0 million for Q4 2025 at aTYR PHARMA, down from $10.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $11.6 million in Q4 2023 and bottomed at $2.4 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $7.4 million, with a median of $8.4 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses skyrocketed 146.43% in 2022, then plummeted 68.21% in 2025.
  • Year by year, Accumulated Expenses stood at $4.0 million in 2021, then surged by 146.43% to $9.9 million in 2022, then increased by 17.21% to $11.6 million in 2023, then dropped by 18.75% to $9.4 million in 2024, then tumbled by 68.21% to $3.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for ATYR at $3.0 million in Q4 2025, $10.2 million in Q3 2025, and $10.3 million in Q2 2025.